BioWorld

May 16, 2011

You're Fired! A Quantitative Analysis of Dissolved Deals

In the first two weeks of this month, pharma firms dissolved four partnerships with biotech companies, continuing a trend that's been troubling the industry. Read More

Is CER the Rx for Personalized Medicine?

Infectious Disease Pipeline Thinner, but Inching Forward

Money Raised Year to Date

Money Raised By Biotech in 2011

Week in Review

Word on the Street

Week in Washington

FDA Approvals in April

Phase I Clinical Trials Update: April 2011

Phase II Clinical Trials Update: April 2011

Phase III Clinical Trials Update: April 2011

American Association for Cancer Research

American College of Cardiology

European Association for the Study of the Liver

Non-U.S. Clinical Trials & Regulatory Actions: April 2011

FDA Submissions, Approvals & Other Actions: April 2011

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

BioWorld briefs for June 11, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 12, 2025.

AI-generated illustration of heart and metabolic impact

Deep Apple signs big Novo deal for cardiometabolic small molecules

BioWorld

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an...

DNA double helix under a magnifying glass

23andme genetic privacy concerns garner Congressional scrutiny

BioWorld MedTech

The bankruptcy of genetic testing service 23andme Holding Corp. prompted a reaction from many quarters, but a June 11 Senate hearing highlighted an interest in...

3Sbio revs on with phase II data in tight PD-1/VEGF bispecific race

BioWorld

3Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert...